Department of Surgery, Broomfield Hospital, Mid and South Essex NHS Trust, Essex, CM1 7ET, UK.
Department of General Internal Medicine, St. Thomas Hospital, London, UK.
Hernia. 2024 Oct;28(5):1679-1685. doi: 10.1007/s10029-024-03022-y. Epub 2024 Mar 28.
Repair of midline ventral incisional hernias (VIHR) requires mesh reinforcement. Mesh types can be categorised into synthetic, biosynthetic, or biological. There is a lack of evidence to support one type of mesh over another. The aim of this pilot study was to compare mesh sensation in patients having undergone elective open repair with synthetic or biosynthetic mesh.
Four years of prospectively collected data were retrospectively reviewed on 40 patients who had undergone VIHR, using either biosynthetic or synthetic mesh placed in the retromuscular plane. The decision on type of mesh used was governed by patient characteristics. Patients were invited to complete the Carolinas Comfort Scale (CCS) questionnaire, the higher the score indicating a poorer quality of life. The maximum length of follow-up was 36 months.
Twenty patients received permanent synthetic and 20 biosynthetic mesh. There was no clinical evidence of hernia recurrence in either group in the short to medium term. Overall, 97% (39/40) patients reported an average of either no or mild symptoms (mean CCS score 17.9 of 115). Patients with a biosynthetic repair had a significant lower CCS at ≥ 18 months (p < 0.05).
After VIHR, patients have low CCS scores, indicating good quality of life outcomes, in the short to medium term irrespective of the mesh used. However, biosynthetic mesh had lower CCS scores in the medium term. This may help surgeons and patients make better informed decisions about which mesh to use in their individual circumstances.
修复中线腹侧切口疝(VIHR)需要进行网片加固。网片类型可分为合成、生物合成或生物。目前缺乏支持一种网片优于另一种网片的证据。本研究旨在比较接受开放式修复的患者中使用合成或生物合成网片的网片感觉。
回顾性分析了 40 例接受 VIHR 的患者的前瞻性收集数据,这些患者使用置于肌后平面的生物合成或合成网片。使用哪种网片的决定取决于患者的特征。邀请患者完成卡罗来纳舒适度量表(CCS)问卷,评分越高表示生活质量越差。最长随访时间为 36 个月。
20 例患者接受永久性合成网片,20 例患者接受生物合成网片。在短期至中期,两组均无临床证据表明疝复发。总体而言,97%(39/40)的患者报告平均无或轻度症状(CCS 平均得分为 115 分中的 17.9 分)。接受生物合成修复的患者在≥18 个月时的 CCS 显著降低(p<0.05)。
在 VIHR 后,患者在短期至中期的 CCS 评分较低,表明生活质量良好,无论使用哪种网片。然而,生物合成网片在中期的 CCS 评分较低。这可能有助于外科医生和患者在个人情况下做出更好的网片使用决策。